WallStSmart

Bio Green Med Solution, Inc. (BGMS)vsBeiGene, Ltd. (ONC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BeiGene, Ltd. generates 376240% more annual revenue ($5.74B vs $1.52M). ONC leads profitability with a 8.9% profit margin vs -204.2%. BGMS trades at a lower P/E of 0.2x. ONC earns a higher WallStSmart Score of 54/100 (C-).

BGMS

Hold

45

out of 100

Grade: D

Growth: 6.3Profit: 2.0Value: 6.7Quality: 5.8
Piotroski: 4/9Altman Z: -77.25

ONC

Buy

54

out of 100

Grade: C-

Growth: 10.0Profit: 6.5Value: 5.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BGMS.

ONCUndervalued (+81.0%)

Margin of Safety

+81.0%

Fair Value

$1847.00

Current Price

$316.01

$1530.99 discount

UndervaluedFair: $1847.00Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BGMS3 strengths · Avg: 10.0/10
P/E RatioValuation
0.2x10/10

Attractively priced relative to earnings

Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
710.0%10/10

Revenue surging 710.0% year-over-year

ONC3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
35.5%10/10

Revenue surging 35.5% year-over-year

EPS GrowthGrowth
16971.0%10/10

Earnings expanding 16971.0% YoY

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Areas to Watch

BGMS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.94M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-46.1%2/10

ROE of -46.1% — below average capital efficiency

Free Cash FlowQuality
$-279,0002/10

Negative free cash flow — burning cash

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
74.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BGMS

The strongest argument for BGMS centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 710.0% demonstrates continued momentum.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.

Bear Case : BGMS

The primary concerns for BGMS are EPS Growth, Market Cap, Return on Equity.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.

Key Dynamics to Monitor

ONC carries more volatility with a beta of 0.49 — expect wider price swings.

BGMS is growing revenue faster at 710.0% — sustainability is the question.

ONC generates stronger free cash flow (161M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ONC scores higher overall (54/100 vs 45/100) and 35.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bio Green Med Solution, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. The company is headquartered in Kuala Lumpur, Malaysia.

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?